Drug could prolong life of cancer patients

Prostate Centre’s Translational Research Initiative for Accelerated Discovery and Development – PC-TRIADD (CECR)

 

OncoGenex Pharmaceuticals could become the poster child for Canada’s new approach to drug discovery. Spun-off from the Vancouver Prostate Centre in 2000, the company, along with its development partner Teva Pharmaceuticals, has demonstrated that its lead product candidate, custirsen (OGX-011), can prolong the lives of patients with advanced prostate cancer. The Prostate Centre’s Translational Research Initiative for Accelerated Discovery and Development is helping OncoGenex reduce the risks and costs associated with getting the drug approved by providing critical pre-clinical development and access to a national clinical trial network. OncoGenex and Teva could apply for regulatory approval of custirsen as early as 2014.

Having really good results with mice is encouraging, but it’s often difficult to translate that success into people. It’s the translation that’s key, which is why you need groups like the Vancouver Prostate Centre and PC-TRIADD. They help de-risk drug development.Scott Cormack, CEO, OncoGenex Pharmaceuticals Inc.